Immunome To Acquire AL102 And AL101 Drug Candidates From Ayala; Immunome Will Pay $20M In Cash And $30M In Immunome Common Stock And Up To $37.5M In Milestones
Portfolio Pulse from Benzinga Newsdesk
Immunome announces the acquisition of AL102 and AL101 drug candidates from Ayala Pharmaceuticals. The deal includes a $20M cash payment and $30M in Immunome common stock, with an additional up to $37.5M in milestone payments.
February 06, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunome's acquisition of AL102 and AL101 could enhance its drug portfolio, involving a $50M upfront payment and potential $37.5M milestones.
The acquisition of AL102 and AL101 could significantly enhance Immunome's drug portfolio, indicating a strategic move to strengthen its position in the pharmaceutical industry. The financial commitment suggests confidence in the potential of these drug candidates. This move is likely to be viewed positively by investors, potentially leading to a short-term uptick in IMNM's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90